BR112021013944A2 - - Google Patents
Info
- Publication number
- BR112021013944A2 BR112021013944A2 BR112021013944A BR112021013944A BR112021013944A2 BR 112021013944 A2 BR112021013944 A2 BR 112021013944A2 BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A2 BR112021013944 A2 BR 112021013944A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2334—Interleukin-34 (IL-34)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305046 | 2019-01-15 | ||
| PCT/EP2020/050920 WO2020148338A1 (en) | 2019-01-15 | 2020-01-15 | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021013944A2 true BR112021013944A2 (US20090163788A1-20090625-C00002.png) | 2021-11-21 |
| BR112021013944A8 BR112021013944A8 (pt) | 2023-02-07 |
Family
ID=65228484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021013944A BR112021013944A8 (pt) | 2019-01-15 | 2020-01-15 | Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias |
Country Status (12)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115819614B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于il34的嵌合抗原受体免疫细胞制备及其应用 |
| WO2023246908A1 (zh) * | 2022-06-21 | 2023-12-28 | 四川大学华西医院 | 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR520E (fr) | 1901-11-13 | 1903-01-26 | Bermont Victor Etienne | Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5) |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| ATE277193T1 (de) | 1989-03-21 | 2004-10-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| ES2338321T3 (es) | 1992-08-21 | 2010-05-06 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| WO1995028494A1 (en) | 1994-04-15 | 1995-10-26 | Targeted Genetics Corporation | Gene delivery fusion proteins |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| IL143797A0 (en) | 1998-12-23 | 2002-04-21 | Pfizer | Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| TWI311564B (en) | 2000-07-03 | 2009-07-01 | Bristol Myers Squibb Compan | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| KR100978836B1 (ko) | 2001-10-19 | 2010-08-30 | 이소테크니카 인코포레이티드 | 신규한 시클로스포린 유사체 미세유화액 예비농축물 |
| NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
| US7488802B2 (en) | 2002-12-23 | 2009-02-10 | Wyeth | Antibodies against PD-1 |
| WO2006012451A2 (en) * | 2004-07-22 | 2006-02-02 | Five Prime Therapeutics, Inc. | Compositions and methods of use for mgd-csf in disease treatment |
| CA3151350A1 (en) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| WO2007076354A2 (en) | 2005-12-20 | 2007-07-05 | Bristol-Myers Squibb Company | Stable protein formulations |
| JP2011512332A (ja) | 2008-02-11 | 2011-04-21 | キュアー テック リミテッド | 腫瘍治療のためのモノクローナル抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| MX2015011374A (es) | 2013-03-15 | 2016-01-15 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (ido). |
| US20160194295A1 (en) | 2013-09-06 | 2016-07-07 | Aurigene Discovery Technologies Limited | 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives as Immunomodulators |
| MY186438A (en) | 2013-09-06 | 2021-07-22 | Aurigene Discovery Tech Ltd | 1, 2, 4-oxadiazole derivatives as immunomodulators |
| EP3169350B1 (en) * | 2014-07-17 | 2019-01-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases |
| CN106084030B (zh) * | 2016-04-25 | 2019-11-08 | 北京大学 | 一种提高白细胞介素il-34热稳定性的方法 |
-
2020
- 2020-01-15 BR BR112021013944A patent/BR112021013944A8/pt unknown
- 2020-01-15 CN CN202080017907.2A patent/CN113508129A/zh active Pending
- 2020-01-15 KR KR1020217024902A patent/KR20210121077A/ko unknown
- 2020-01-15 US US17/422,556 patent/US20220098264A1/en active Pending
- 2020-01-15 SG SG11202107606VA patent/SG11202107606VA/en unknown
- 2020-01-15 AU AU2020208909A patent/AU2020208909A1/en active Pending
- 2020-01-15 JP JP2021540589A patent/JP2022517029A/ja active Pending
- 2020-01-15 CA CA3126741A patent/CA3126741A1/en active Pending
- 2020-01-15 MX MX2021008525A patent/MX2021008525A/es unknown
- 2020-01-15 WO PCT/EP2020/050920 patent/WO2020148338A1/en unknown
- 2020-01-15 EP EP20700307.0A patent/EP3911670A1/en active Pending
-
2021
- 2021-07-14 IL IL284868A patent/IL284868A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL284868A (en) | 2021-08-31 |
| AU2020208909A1 (en) | 2021-07-29 |
| US20220098264A1 (en) | 2022-03-31 |
| CA3126741A1 (en) | 2020-07-23 |
| KR20210121077A (ko) | 2021-10-07 |
| JP2022517029A (ja) | 2022-03-03 |
| EP3911670A1 (en) | 2021-11-24 |
| WO2020148338A1 (en) | 2020-07-23 |
| CN113508129A (zh) | 2021-10-15 |
| MX2021008525A (es) | 2021-11-12 |
| BR112021013944A8 (pt) | 2023-02-07 |
| SG11202107606VA (en) | 2021-08-30 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; NANTES UNIVERSITE (FR) |